Chronic active antibody-mediated rejection (cAMR) is a major determinant of late allograft failure. Rituximab/immunoglobulins (IVIg) + plasma exchange (PLEX) showed controversial results in cAMR treatment. Tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, has been recently used as rescue therapy in patients non-responsive to rituximab/IVIg/PLEX with favorable outcomes. Whether TCZ acts "per se" or requires a priming effect from previous treatments is currently unknown.

Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation

Lavacca, Antonio;Presta, Roberto;Gai, Chiara;Mella, Alberto;Gallo, Ester;Camussi, Giovanni;Abbasciano, Isabella;Barreca, Antonella;Caorsi, Cristiana;Fop, Fabrizio;Messina, Maria;Biancone, Luigi
2020

Abstract

Chronic active antibody-mediated rejection (cAMR) is a major determinant of late allograft failure. Rituximab/immunoglobulins (IVIg) + plasma exchange (PLEX) showed controversial results in cAMR treatment. Tocilizumab (TCZ), a humanized anti-interleukin 6 receptor antibody, has been recently used as rescue therapy in patients non-responsive to rituximab/IVIg/PLEX with favorable outcomes. Whether TCZ acts "per se" or requires a priming effect from previous treatments is currently unknown.
e13908
e13908
Chronic antibody-mediated rejection; Kidney transplantation; Tocilizumab; Transplant glomerulopathy; angiotensin II type I-receptor antibody; anti-HLA antibody; donor specific antibodies
Lavacca, Antonio; Presta, Roberto; Gai, Chiara; Mella, Alberto; Gallo, Ester; Camussi, Giovanni; Abbasciano, Isabella; Barreca, Antonella; Caorsi, Cristiana; Fop, Fabrizio; Messina, Maria; Rossetti, Maura; Biancone, Luigi
File in questo prodotto:
File Dimensione Formato  
ctr.13908-1-20.pdf

Accesso aperto con embargo fino al 16/06/2021

Descrizione: Articolo principale
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 8.46 MB
Formato Adobe PDF
8.46 MB Adobe PDF Visualizza/Apri
ctr.13908-21-30.pdf

Accesso aperto con embargo fino al 16/06/2021

Descrizione: Articolo principale
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 9.09 MB
Formato Adobe PDF
9.09 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1741500
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 30
social impact